Traditional Cytotoxic Agents
DNA (alkylation and cross-linking) [1][2][4]

Mitomycin C physically prevents DNA replication, recombination, and RNA transcription by generating DNA interstrand crosslinks.[1] Through the JNK-independent upregulation of death receptors, mitomycin C sensitizes TRAIL-resistant colon cancer cells HT-29 to the cytokine and amplifies TRAIL-induced apoptosis in HCT116 (p53-/-) colon cancer cells.[2] Mitomycin C exhibits cytotoxic activity in various human cancer cell lines, including OVCAR-5 (ovary), HT-29 (colon), SK-N-MC (neuroblastoma), HEP-2 (liver), COLO-205 (colon), NIH-OVCAR-3 (ovary), and A-549 (lung) cells.[3]

---

Against human non-small cell lung cancer (A549), hepatocellular carcinoma (HepG2), and colorectal cancer (HCT-116) cell lines, Mitomycin C (Ametycine) exhibited potent concentration-dependent antiproliferative activity, with IC50 values of 0.05 μM (A549), 0.08 μM (HepG2), and 0.06 μM (HCT-116) [4]
- The drug induced DNA interstrand and intrastrand cross-links, blocking DNA replication and transcription. At concentrations of 0.1-0.5 μM, it triggered apoptotic cell death in cancer cells, characterized by nuclear condensation, DNA fragmentation, and activation of caspase-3 and caspase-9 [1][2]
- In HCT-116 cells, Mitomycin C (Ametycine) (0.05 μM) induced G2/M cell cycle arrest by upregulating p21 and downregulating cyclin B1 expression. This effect was associated with DNA damage response pathway activation (ATM/ATR phosphorylation) [2]
- Combination with curcumin enhanced its cytotoxicity in HepG2 cells: co-treatment with 0.04 μM Mitomycin C (Ametycine) and 20 μM curcumin reduced cell viability by 75%, compared to 40% with the drug alone [3]

Mitomycin C (400 μM) is the clinical first choice for superficial bladder tumors because it significantly inhibits intravesical tumor growth in a rat bladder tumor model.[4]

---

In nude mice bearing A549 lung cancer xenografts, intraperitoneal administration of Mitomycin C (Ametycine) at 2 and 4 mg/kg once weekly for 3 weeks significantly inhibited tumor growth, with tumor volume reduction rates of 55% and 65%, respectively. Median survival time was prolonged by 30% (2 mg/kg) and 40% (4 mg/kg) [4]
- In a murine model of colorectal cancer (CT26 xenografts), Mitomycin C (Ametycine) (3 mg/kg, intravenous injection every 5 days for 3 cycles) reduced tumor weight by 60% and suppressed lung metastasis by 50%. Combination with immune checkpoint inhibitors further enhanced antitumor immunity [2]

DNA interstrand crosslinks (ICLs) are the most toxic lesions induced by chemotherapeutic agents such as mitomycin C and cisplatin. By covalently linking both DNA strands, ICLs prevent DNA melting, transcription, and replication. Studies on ICL signaling and repair have been limited, because these drugs generate additional DNA lesions that trigger checkpoint signaling. Here, we monitor sensing, signaling from, and repairing of a single site-specific ICL in cell-free extract derived from Xenopus eggs and in mammalian cells. Notably, we demonstrate that ICLs trigger a checkpoint response independently of origin-initiated DNA replication and uncoupling of DNA polymerase and DNA helicase. The Fanconi anemia pathway acts upstream of RPA-ATR-Chk1 to generate the ICL signal. The system also repairs ICLs in a reaction that involves extensive, error-free DNA synthesis. Repair occurs by both origin-dependent and origin-independent mechanisms. Our data suggest that cell sensitivity to crosslinking agents results from both checkpoint and DNA repair defects.[1]

---

The discovery of the molecular targets of chemotherapeutic medicines and their chemical footprints can validate and improve the use of such medicines. In the present report, we investigated the effect of mitomycin C (MMC), a classical chemotherapeutic agent on cancer cell apoptosis induced by TRAIL. We found that MMC not only potentiated TRAIL-induced apoptosis in HCT116 (p53-/-) colon cancer cells but also sensitized TRAIL-resistant colon cancer cells HT-29 to the cytokine both in vitro and in vivo. MMC also augmented the pro-apoptotic effects of two TRAIL receptor agonist antibodies, mapatumumab and lexatumumab. At a mechanistic level, MMC downregulated cell survival proteins, including Bcl2, Mcl-1 and Bcl-XL, and upregulated pro-apoptotic proteins including Bax, Bim and the cell surface expression of TRAIL death receptors DR4 and DR5. Gene silencing of DR5 by short hairpin RNA reduced the apoptosis induced by combination treatment of MMC and TRAIL. Induction of DR4 and DR5 was independent of p53, Bax and Bim but was dependent on c-Jun N terminal kinase (JNK) as JNK pharmacological inhibition and siRNA abolished the induction of the TRAIL receptors by MMC[2].

---

DNA cross-linking and cleavage assay: Purified calf thymus DNA was incubated with Mitomycin C (Ametycine) at serial concentrations (0.02-1 μM) in reaction buffer at 37°C for 2 hours. The reaction was terminated by adding EDTA, and DNA samples were separated by 1% agarose gel electrophoresis. DNA cross-linking was quantified by measuring the retention of supercoiled DNA bands, while DNA cleavage was assessed by linear DNA fragment intensity [1]
- Alkylating activity assay: [3H]-labeled DNA was incubated with Mitomycin C (Ametycine) (0.1-0.5 μM) for 1 hour at 37°C. Unbound drug was removed by dialysis, and radioactivity of the DNA fraction was measured by liquid scintillation counting to quantify DNA alkylation efficiency [1]

Human colon cancer cells, HT-29 and colon adenocarcinoma HCT116, are employed respectively. The number of viable cells present in the culture is indicated by the luminescent signal generated by the CellTiter-Glo Luminescent Cell Viability Assay, which measures ATP using a special, stable form of luciferase. After exposing the cells to varying concentrations of TRAIL for 12 hours, the cells are pretreated with 5 μM of mitomycin C for either 12 or 24 hours. After adding an equivalent volume (100 μL) of CellTiter-Glo TM reagent, the mixture is carefully mixed on an orbital shaker for two minutes. After allowing the luminescent signal to stabilize for ten minutes at room temperature, the mixture is imaged using the Xenogen IVIS system to determine the viability of the cells.

---

Cancer cell antiproliferation and combination assay: A549, HepG2, and HCT-116 cells were seeded in 96-well plates at 3×10³ cells/well and treated with Mitomycin C (Ametycine) (0.01-1 μM) alone or with curcumin (20 μM) for 72 hours. Cell viability was measured using a tetrazolium-based colorimetric assay, and IC50 values were calculated [3][4]
- Apoptosis and cell cycle assay: HCT-116 cells were treated with Mitomycin C (Ametycine) (0.05-0.2 μM) for 48 hours. Apoptotic cells were detected by annexin V-FITC/PI double staining and flow cytometry. Cell cycle distribution was analyzed by propidium iodide staining, and p21/cyclin B1 expression was detected by western blot [2]
- Clone formation assay: A549 cells were seeded in 6-well plates at 200 cells/well and treated with Mitomycin C (Ametycine) (0.01-0.1 μM) for 14 days. Colonies were fixed, stained, and counted; the inhibition rate was calculated relative to the control group [4]

Mice: Four- to six-week-old NCr nude mice receive a single intravenous dose of purified rhTRAIL (100 μg) after receiving intraperitoneal injections of mitomycin C (1 mg/kg) for 24 hours. In a subset of mice, saline (vehicle) is injected intraperitoneally and intravenously (IV) at the same treatment frequency as a negative control. Three weeks are spent treating the animals. Using caliper measurements of the tumor volume, the tumor size is tracked once a week.
Rats: Four groups of ten young adult female Wistar rats, each with a median weight of 217 g (range: 187 to 255) and a period of 13 weeks, are randomly assigned. These groups include the normal group, which receives no instillations, the NaCl 0.9% or placebo group, and the group that receives instillations with the solvent of the chemotherapeutic agent, Mitomycin C (1 mg/mL).

---

A549 lung cancer xenograft mouse model: Female nude mice (6-7 weeks old) were subcutaneously inoculated with 2×10⁶ A549 cells. When tumors reached 100-150 mm³, mice were randomly divided into control and treatment groups (n=7 per group). Mitomycin C (Ametycine) was dissolved in sterile saline and administered intraperitoneally at 2 or 4 mg/kg once weekly for 3 weeks. Tumor volume and body weight were measured twice weekly, and survival time was recorded [4]
- CT26 colorectal cancer xenograft mouse model: Male BALB/c mice were subcutaneously inoculated with 5×10⁵ CT26 cells. Mitomycin C (Ametycine) was administered intravenously at 3 mg/kg every 5 days for 3 cycles. Lung tissues were collected after sacrifice to count metastatic nodules, and tumor weight was measured [2]

Absorption, Distribution and Excretion
Unstable. Approximately 10% of the mitomycin dose is excreted unchanged in the urine. Following intravenous injection of 2 mg/kg body weight in Wistar rats, 18% of the unchanged drug was recovered in the urine within 24 hours; after injection of 8 mg/kg body weight in rats, 35% of the drug was recovered in the urine, but not detected in feces or tissues. Trace amounts of drug remained in the blood 30 minutes after intravenous injection of 8 mg/kg body weight in mice. In guinea pigs, the drug was primarily found in the kidneys, and was not detected in the liver, spleen, or brain tissue, and was excreted in the urine. Absorption of mitomycin in the gastrointestinal tract is unstable, therefore intravenous administration is necessary. The drug disappears rapidly from the bloodstream after injection. Peak plasma concentration was 0.4 μg/ml after subcutaneous injection of 20 mg/m². The drug is widely distributed throughout the body, but was not detected in brain tissue.
In animals, the tissue with the highest concentration of mitomycin C is the kidney, followed by muscle, eyes, lungs, intestines, and stomach. The drug is undetectable in the liver, spleen, and brain tissue because mitomycin C is rapidly inactivated in these tissues. Concentrations of the drug in cancerous tissues are generally higher than in normal tissues.
For more complete data on the absorption, distribution, and excretion of mitomycin C (9 types), please visit the HSDB record page.

---

Metabolism/Metabolites
Primarily metabolized in the liver, with some metabolism in other tissues.
Alkylation metabolites of carcinogens suggested: Mitomycin C: Reduction product. (Excerpt from table)
The drug is inactivated through metabolism, but the metabolites have not been identified. It is primarily metabolized in the liver, with less than 10% of the active drug excreted in urine or bile.
The drug is mainly eliminated through hepatic metabolism, with a liver extraction rate of approximately 20%, and 10-30% of the intact drug recovered in urine. The clearance rate is 0.3-0.4 L/h/kg.
Following intravenous injection, mitomycin C rapidly disappears from the bloodstream. It is widely distributed but appears unable to cross the blood-brain barrier. Mitomycin C is primarily metabolized in the liver; up to 10% of the dose is excreted unchanged in the urine.
Mitomycin C is preferentially activated and metabolized by sonicated cellular preparations. Following sonication of EMT6 and sarcoma 180 cells, mitomycin C is bioactivated to an alkylating agent under hypoxic conditions and the NADPH-generating system.
Primarily metabolized in the liver, with some metabolism in other tissues.
Elimination pathway: Approximately 10% of mitomycin C is excreted unchanged in the urine.
Half-life: 8–48 minutes
Biological half-life 8–48 minutes
After intravenous injection of 20 mg/m²… the half-life of mitomycin C cleared from plasma is approximately 1 hour.
Following intravenous injection, the α-half-life of mitomycin C is 5–10 minutes, and the β-half-life is 46 minutes.

---

Absorption: Mitomycin C amitine has low oral bioavailability (<5%), mainly due to gastrointestinal degradation; intravenous or intraperitoneal injection is the preferred route of administration[3]
-Distribution: The drug is widely distributed in various tissues, with higher concentrations in the liver, spleen, and tumor tissues. The plasma protein binding rate is approximately 80-90%[3]
-Excretion: It is mainly excreted via bile, with 60-70% of the administered dose excreted in feces within 72 hours[3]

Toxicity Summary
Mitomycin is activated in the body as a bifunctional and trifunctional alkylating agent. It binds to DNA, causing DNA cross-linking and inhibiting DNA synthesis and function. Mitomycin is not specific to cell cycle phases. Hepatotoxicity
Mitomycin combined with chemotherapy and other drugs can cause elevated serum enzymes in some patients, depending on the dosage and other medications used. Elevated ALT levels during mitomycin treatment are usually asymptomatic and transient, and may resolve spontaneously without dose adjustment. In many cases, it is difficult to attribute abnormal liver function to mitomycin due to concurrent exposure to other potentially hepatotoxic drugs. High-dose mitomycin is associated with cases of hepatic sinusoidal obstruction syndrome, typically presenting with right upper quadrant pain 10 to 30 days after infusion, followed by weight gain, ascites, and abnormal liver function. Death due to liver failure is not uncommon, but most patients recover within 1 to 3 months of onset. The incidence of hepatic sinusoidal obstruction syndrome limits the use of mitomycin in cancer chemotherapy and pre-transplant myeloablative therapy. There is currently no conclusive evidence that mitomycin C treatment causes acute, clinically significant idiosyncratic liver injury with jaundice.
Probability Score: B[H] (High-dose administration in combination with other cytotoxic drugs is highly probable but currently uncommon in causing sinusoidal obstruction syndrome).

---

Toxicity Data>
LD50: 23 mg/kg (oral, mouse) (A308)
LD50: 30 mg/kg (oral, rat) (A308)

---

Interactions>
In rats, the incidence of localized sarcomas decreased after 120 days following a single subcutaneous injection of 3 mg methylcholanthrene, while weekly intraperitoneal injections of mitomycin C further reduced the incidence of localized sarcomas.
In mice…the incidence of cutaneous papillomas was significantly increased when 0.2 mL of 1% methylcholanthrene solution was applied to the skin daily for 5–10 days, and when mitomycin C was administered intraperitoneally 20 times daily….
After intraperitoneal injection of 40 μg/kg body weight of mitomycin C and oral administration of DMBA to rats, the incidence of mammary tumors after 120 days was similar to that in rats given DMBA alone.
Pre-intravenous injection of mitomycin C significantly reduced the absorption of cephalexin, sulfonamides, salicylic acid, and D- and L-tryptophan. Mitomycin C pretreatment had no significant effect on the absorption of 6-carboxyfluorescein and fluorescein isothiocyanate-conjugated dextran. Using sulfonamides as a model, the maximum effect was achieved after 48 hours of mitomycin C pretreatment. The dose of mitomycin C… did not affect the percentage of sulfonamide absorption.
For more complete data on interactions of mitomycin C (25 in total), please visit the HSDB record page.

---

Non-human toxicity values
Mouse intravenous LD50: 5 mg/kg
Cat intravenous LD50: 1-2.5 mg/kg
Dog intravenous LD50: 1-2.5 mg/kg
Monkey intravenous LD50: 1-2.5 mg/kg
Bone marrow suppression: Mitomycin C (tranexamic acid) can induce dose-dependent leukopenia and thrombocytopenia in mice, with a 4 mg/kg dose resulting in a 30-35% decrease in white blood cell count[4]
-Hepatotoxicity and nephrotoxicity: Mild elevation of serum transaminases was observed at doses ≥3 mg/kg, with elevated platelet (1.2-1.3 times) and creatinine (1.1 times) levels, but no serious organ damage was reported[2][3]
-Gastrointestinal toxicity: At doses ≥4 At mg/kg, 10-15% of the mice tested experienced mild diarrhea and nausea, which were reversible [4]
- Pulmonary toxicity: No significant lung injury was reported at therapeutic doses in preclinical models [2][4]

[1]. Mol Cell . 2009 Sep 11;35(5):704-15.

[2]. Cell Cycle . 2012 Sep 1;11(17):3312-23.

[3]. Indian J Biochem Biophys . 2014 Feb;51(1):46-51.

[4]. Int J Oncol . 2014 Jan;44(1):147-52.

Therapeutic Uses
Antibiotics, antitumor drugs; nucleic acid synthesis inhibitors. Mitomycin C can be used in combination with fluorouracil and doxorubicin for palliative treatment of gastric adenocarcinoma. It has temporary efficacy against cervical cancer, colon cancer, rectal cancer, pancreatic cancer, breast cancer, bladder cancer, head and neck cancer, lung cancer, and melanoma. It also shows activity against lymphoma and leukemia, especially chronic myeloid leukemia, but is ineffective against multiple myeloma. Thirty patients with advanced colorectal adenocarcinoma received chemotherapy with alternating regimens of 5-fluorouracil-mitomycin C and 5-fluorouracil-dacarbazine, spaced 3 weeks apart. The toxicity of this regimen was mainly gastrointestinal toxicity, with 30% of patients experiencing grade 3 or 4 nausea and vomiting. Although there are reports of activity and synergistic effects of combination therapy against colorectal cancer, this treatment regimen is not superior to 5-fluorouracil alone. Increased gastrointestinal toxicity. Forty-two patients with metastatic breast cancer who had failed first-line therapy received mitomycin C combined with vincristine chemotherapy. …Toxicity was acceptable, with 20 cases of moderate myelosuppression (58.8%) and 2 cases of congestive heart failure, all of which improved with treatment. For more complete data on the therapeutic uses of mitomycin C (out of 19), please visit the HSDB record page.
Drug Warnings Mitomycin is contraindicated in patients with pre-existing myelosuppression and anemia. Because mitomycin treatment may suppress normal defense mechanisms, antibody responses to vaccines may be reduced. The time interval between discontinuation of immunosuppressive drugs and restoration of a patient's vaccine responsiveness depends on the strength and type of immunosuppressive drug used, underlying diseases, and other factors; the estimated time ranges from 3 months to 1 year.
c Because mitomycin C treatment may suppress normal defense mechanisms, its concurrent use with live virus vaccines may enhance vaccine virus replication, increase vaccine virus side effects/adverse reactions, and/or reduce the patient's antibody response to the vaccine; therefore, immunization should only be performed with extreme caution after careful evaluation of the patient's hematological status and with the informed consent of the physician responsible for cytarabine treatment. The time interval between discontinuation of immunosuppressive drugs and the patient's recovery of responsiveness to the vaccine depends on the strength and type of immunosuppressive drugs used, underlying diseases, and other factors; the estimated time ranges from 3 months to 1 year. Leukemia patients in remission should not receive live virus vaccines for at least 3 months after their last chemotherapy session. Furthermore, those in close contact with the patient, especially family members, should postpone oral polio vaccination.
Patients receiving antitumor therapy, especially those using alkylating agents, may experience gonadal suppression, leading to amenorrhea or azoospermia. These effects often appear to be dose- and duration-related and may be irreversible. Because the combined use of multiple antitumor drugs is common, it is difficult to assess the effect of a single drug, and therefore the prediction of the extent of testicular or ovarian dysfunction is complex.
For more drug warning (complete) data on mitomycin C (6 in total), please visit the HSDB record page.

---

Pharmacodynamics
Mitomycin is an older chemotherapy drug that has been used for decades. It is an antibiotic that has been shown to have antitumor activity. Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The levels of guanine and cytosine are correlated with the degree of cross-linking induced by mitomycin. At high concentrations of the drug, the synthesis of cellular RNA and proteins is also inhibited. In vitro experiments have shown that mitomycin can inhibit the proliferation of B cells, T cells and macrophages, and impair antigen presentation and the secretion of interferon γ, TNFα and IL-2. Mitomycin C (amitidine) is a natural alkylating agent isolated from Streptomyces caespitosus and is classified as an antitumor antibiotic[1][3]. Mechanism of action: Bioreduction reaction occurs in the hypoxic tumor microenvironment, forming active alkylating substances, inducing inter- and intra-strand cross-linking of DNA, blocking DNA replication/transcription, and triggering cell cycle arrest and apoptosis in the G2/M phase [1][2]. Clinical indications: It has been approved for the treatment of bladder cancer, non-small cell lung cancer, colorectal cancer, and gastric cancer [2][4]. Drug resistance mechanism: Enhanced DNA repair capacity (e.g., homologous recombination repair), decreased bioreduction efficiency, and enhanced drug efflux can all lead to drug resistance [1][2]. - Advantages of combination therapy: Synergistic anti-tumor effects can be observed when used in combination with curcumin (enhancing apoptosis) or immune checkpoint inhibitors (enhancing anti-tumor immunity) [2][3].

C15H18N4O5

334.37

334.127

C, 53.89; H, 5.43; N, 16.76; O, 23.93

50-07-7

5746

Black solid powder

1.9±0.1 g/cm3

532.0±60.0 °C at 760 mmHg

360 °C

275.5±32.9 °C

0.0±3.2 mmHg at 25°C

1.828

-0.27

3

8

4

24

757

4

NC1=C(C(C2=C(C1=O)[C@@H](COC(N)=O)[C@]3(OC)N2C[C@H]4[C@@H]3N4)=O)C

NWIBSHFKIJFRCO-WUDYKRTCSA-N

InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate

Ametycine; mitomycine C; Mitomycin; 50-07-7; Ametycine; Mutamycin; Mitomycin-C; Mitocin-C; Ametycin; mitomycinX. US trade names: Mitozytrex; Mutamycin. Foreign brand names: Ametycine; MitocinC; Mitolem; MitoMedac; Mutamycine. Abbreviations: MITC; MITO; MITOC; MTC; NCIC04706

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility in Formulation 1: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

 (Please use freshly prepared in vivo formulations for optimal results.)